HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No More ‘Major’ Deals For GSK Consumer Before IPO – CEO Walmsley

Executive Summary

GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO. 

You may also be interested in...



GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales

GSK is plotting further divestments into next year as it looks to focus its portfolio on key categories and raise funds to cover the costs of integrating Pfizer's Consumer Healthcare business. In the third quarter, GSK's sales advanced double-digits thanks to the inclusion of Pfizer megabrands like Advil and Centrum.

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Under Brian McNamara’s leadership, GSK Consumer Healthcare has begun to assemble a management team that combines talent from both GSK and Pfizer.

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel